Moderna has received FDA approval for a new lower-dose COVID-19 vaccine, with restrictions on who can use it. The vaccine, mNexspike, is designed to be one-fifth the dose of its current vaccine, Spikevax. It will be available to adults 65 and older, and people aged 12-64 with certain health conditions.
The FDA’s approval is based on a study of 11,400 participants, which found the new vaccine to be safe and effective, comparable to the original shot. Moderna expects to offer both vaccines this fall.
This move reflects a shift in approach from previous COVID-19 vaccine distribution, with skepticism about vaccine effectiveness among some officials. The decision comes after the Trump administration canceled funding for Moderna’s potential pandemic flu vaccine development.
Source: https://abcnews.go.com/Business/wireStory/fda-approves-modernas-new-lower-dose-covid-19-122382791